Literature DB >> 24385223

Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer.

R Sawaya1, W Radwan, S Hammoud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24385223     DOI： 10.1007/s12032-013-0831-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  6 in total

1.  Reversible posterior leukoencephalopathy syndrome and bevacizumab.

Authors:  Peter Glusker; Larry Recht; Barton Lane
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

Review 2.  Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.

Authors:  R C S Seet; A A Rabinstein
Journal:  QJM       Date:  2011-08-24

3.  Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns.

Authors:  Oliver Kastrup; Markus Gerwig; Markus Frings; Hans-Christoph Diener
Journal:  J Neurol       Date:  2011-12-22       Impact factor: 4.849

4.  Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.

Authors:  Jeffrey A Allen; Ashish Adlakha; Peter R Bergethon
Journal:  Arch Neurol       Date:  2006-10

Review 5.  The posterior reversible encephalopathy syndrome: what's certain, what's new?

Authors:  C Roth; A Ferbert
Journal:  Pract Neurol       Date:  2011-06

Review 6.  Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Authors:  Camille Tlemsani; Olivier Mir; Pascaline Boudou-Rouquette; Olivier Huillard; Karin Maley; Stanislas Ropert; Romain Coriat; François Goldwasser
Journal:  Target Oncol       Date:  2011-11-17       Impact factor: 4.493
  6 in total
  5 in total

Review 1.  New ways to successfully target tumor vasculature in ovarian cancer.

Authors:  Xiaoyun Yang; Fangrong Shen; Wei Hu; Robert L Coleman; Anil K Sood
Journal:  Curr Opin Obstet Gynecol       Date:  2015-02       Impact factor: 1.927

2.  Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.

Authors:  Narimane Salmi; Ibrahim Elghissassi; Khadija Bellahammou; Asmaa Lakhdissi; Hind Mrabti; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2014-10-21

3.  Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer.

Authors:  Mohsin Hamid; Ali Ghani; Ida Micaily; Usman Sarwar; Bilal Lashari; Faizan Malik
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-06-12

4.  Chemotherapy-induced posterior reversible encephalopathy syndrome: Three case reports.

Authors:  Bernardo Cacho-Díaz; Nydia A Lorenzana-Mendoza; Karen Salmerón-Moreno; Gervith Reyes-Soto; Carlos Castillo-Rangel; Roberto Corona-Cedillo; Salvador Escobar-Ceballos; Jaime G de la Garza-Salazar
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 5.  Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature.

Authors:  Luigi Carlo Turco; Gabriella Ferrandina; Virginia Vargiu; Serena Cappuccio; Anna Fagotti; Giuseppina Sallustio; Giovanni Scambia; Francesco Cosentino
Journal:  Ann Transl Med       Date:  2020-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.